文献速递肿瘤 PET/CT

局部晚期鼻咽癌放疗后12周PET/CT与液体活检监测研究

[18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-01

该前瞻性研究纳入506例III-IVa期局部晚期鼻咽癌患者,在放疗后12周行PET/CT及循环游离EBV DNA检测,评估其对局部残留和/或远处转移的阴性预测值。12周PET/CT对总体残留和/或转移的NPV为96.3%,敏感性72.4%,特异性93.3%;12周cfEBV DNA的NPV为91.7%,敏感性41.7%,特异性34.5%。结论认为12周PET/CT是可靠的监测工具,联合cfEBV DNA可提供风险分层信息。

要点

  • 放疗后12周PET/CT对局部残留和/或远处转移的NPV达96.3%,阴性结果可靠。
  • 12周cfEBV DNA的NPV为91.7%,但敏感性仅41.7%,单独使用易漏诊。
  • cfEBV DNA不可检测者PET/CT的NPV为96.8%,可检测者PET/CT敏感性为85.0%。

核心结论

  • 放疗后12周PET/CT是局部晚期鼻咽癌监测的可靠工具,有助于优化随访策略并及时干预。
  • PET/CT与cfEBV DNA联合使用可为患者管理提供有价值的风险分层信息。

研究设计与样本

  • 前瞻性纳入2018至2021年506例III-IVa期局部晚期鼻咽癌患者,中位随访45.2个月。
  • 放疗前及放疗后12周行PET/CT,放疗前及放疗后4、12、24周检测cfEBV DNA,后续每3至6个月复查。
  • 主要终点为12周PET/CT识别局部残留和/或远处转移的阴性预测值。

主要发现

  • 放疗后12周局部残留22例(4.3%),远处转移30例(5.9%),两者兼有6例(1.2%)。
  • 12周PET/CT对总体残留和/或转移的NPV为96.3%,敏感性72.4%,特异性93.3%,PPV为58.3%,准确性90.9%。
  • 12周cfEBV DNA对应NPV为91.7%,敏感性41.7%,特异性34.5%,PPV为93.8%,准确性87.0%。
  • 12周cfEBV DNA不可检测者PET/CT的NPV为96.8%,可检测者PET/CT敏感性为85.0%。

关键数值与推荐

  • 12周PET/CT:NPV 96.3%、敏感性72.4%、特异性93.3%、PPV 58.3%、准确性90.9%。
  • 12周cfEBV DNA:NPV 91.7%、敏感性41.7%、特异性34.5%、PPV 93.8%、准确性87.0%。
  • cfEBV DNA不可检测者PET/CT的NPV为96.8%;可检测者PET/CT敏感性为85.0%。

临床怎么用

  • 对局部晚期鼻咽癌患者,放疗后12周可行PET/CT评估残留和远处转移,阴性结果可支持继续随访。
  • 结合12周cfEBV DNA水平进行风险分层:不可检测者PET/CT阴性预测值更高,可检测者需警惕并考虑PET/CT敏感性提升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In nasopharyngeal carcinoma (NPC), the 12-week period following radiotherapy (RT) represents a critical surveillance window for detecting residual disease and distant metastasis. We aim to assess the role of PET/CT And cfEBV DNA levels at 12 weeks post-RT in the surveillance of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). METHODS: Patients with stage III-IVa LA-NPC were included. PET/CT scans were conducted both pre-treatment And at 12 weeks post-RT. cfEBV DNA was assessed pre-treatment, at 4, 12, And 24 weeks post-RT, And subsequently at 3- to 6-month intervals. The primary endpoint was the negative predictive value (NPV) of 12-week PET/CT for identifying locoregional residual disease (RD) and/or distant metastasis (DM). RESULTS: Between 2018 And 2021, 506 eligible patients were prospectively enrolled (median follow-up: 45.2 months). At 12 weeks post-RT, RD was identified in 22 patients (4.3%), DM in 30 patients (5.9%), And both RD And DM in 6 patients (1.2%). For overall RD and/or DM, 12-week PET/CT demonstrated An NPV of 96.3%, sensitivity of 72.4%, specificity of 93.3%, positive predictive value (PPV) of 58.3%, And accuracy of 90.9%. The corresponding values for 12-week cfEBV DNA were An NPV of 91.7%, sensitivity of 41.7%, specificity of 34.5%, PPV of 93.8%, And accuracy of 87.0%. Among subgroups defined by 12-week cfEBV DNA levels, patients with undetectable cfEBV DNA showed a 96.8% NPV for PET/CT, whereas those with detectable cfEBV DNA demonstrated an 85.0% sensitivity for PET/CT. CONCLUSION: PET/CT performed at 12 weeks post-RT is a reliable tool for surveillance in LA-NPC, facilitating the optimization of follow-up strategies and enabling timely therapeutic interventions. The combined use of PET/CT and cfEBV DNA provides valuable risk-stratified insights for managing patients effectively.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu LT, Yang ZC, He JR, et al. [18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 41032079. doi:10.1007/s00259-025-07529-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。